共 50 条
- [41] A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2)JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Shu, PeiLi, XiaoyuYuan, LiXie, HuiZhou, QiWang, YongshengLi, QiuZheng, Li
- [42] ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I/II studyANNALS OF ONCOLOGY, 2022, 33 (07) : S886 - S887Laubli, H.Alonso, G.Lopez, J. S.Calvo, E.Joerger, M.Perez, V.Di Blasi, D.Nair, A.Richter, K.Huber, C.Mouton, J.Costanzo, S.Jethwa, S.Bucher, C. M.Garralda, E.
- [43] PHASE 1/2 STUDY OF THOR-707 (SAR444245), A PEGYLATED RECOMBINANT NON-ALPHA IL-2, AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB OR CETUXIMAB IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A511 - A511Falchook, GeraldGan, HuiFu, SiqingMcKean, MeredithAzad, ArunSommerhalder, DavidWang, JudyTan, TiraChee, ChenBarve, MinalLemeque, CharlotteAcuff, NicolePham, HeleneMooney, JillWang, RuiMarina, NeyssaAbbadessa, GiovanniMeniawy, Tarek
- [44] A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumorsMOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3346S - 3346SSpratlin, Jennifer L.Eckhardt, S. GailGore, LiaCamidge, D. RossLeong, StephenO'Bryant, CindyDiab, SamiChow, Laura Q. M.Youssoufian, HagopFox, FloydCohen, Roger B.
- [45] IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 ß/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Starodub, AlexanderGabrail, Nashat Y.Zhang, YingCastro, Davis Y. TorrejonSlavsky, SibelSingel, Stina MuiPowderly, John D.
- [46] A PHASE 2, MULTI-ARM STUDY OF ANTI-CD47 ANTIBODY, MAGROLIMAB, IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A554 - A554Subbiah, VivekVaishampayan, UlkaPuri, SonamLin, LanjiaChao, MarkRamsingh, GiriKummar, ShivaaniStrauss, JamesPatel, Sandip
- [47] Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Coward, JermaineAbed, AfafNagrial, AdnanMarkman, Ben
- [48] Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumorsANNALS OF ONCOLOGY, 2024, 35 : S686 - S686Perez, D. RodaZugazagoitia, J.Garralda, E.Spira, A. I.El-Khoueiry, A. B.Zhao, Y.Oppelt, P.Lin, X.Xie, S.Chen, M.Gan, J.Wong, G.Pollard, J. RussellaHedrich, W.Pallante, J.Adrian, F.Schweizer, L.Shi, X.Andtbacka, R. H. I.
- [49] A phase I/II study of ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Läubli, HeinzAlonso, GuzmanSuzanne Lopez, JuanitaCalvo, EmilianoSanchez Perez, VickyDi Blasi, DanielaNair, AswathyRichter, KirstenHuber, ChristophEgli, NicoleMouton, JulieCostanzo, SilvioKatopodis, AndreasJethwa Schnetzler, SangeetaMarcus Bucher, ChristophGarralda, Elena
- [50] Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor ßγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Garralda, ElenaNaing, AungGalvao, VladimirLoRusso, PatriciaGrell, PeterCassier, Philippe AlexandreGomez-Roca, Carlos A.Korakis, IphigenieBechard, DavidJelinkova, Lenka PalovaAdkins, IrenaTillmanns, SaschaKiemle-Kallee, JoachimMarabelle, AurelienChampiat, Stephane